Political priority and pathways to scale-up of childhood cancer care in five nations.
Adolescent
Child
Child, Preschool
Developing Countries
El Salvador
Ghana
Government Programs
/ organization & administration
Guatemala
Health Policy
Health Priorities
Health Services Needs and Demand
/ organization & administration
Healthcare Disparities
Humans
India
Infant
Infant, Newborn
Neoplasms
/ therapy
Philippines
Policy Making
Politics
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
03
2019
accepted:
02
08
2019
entrez:
20
8
2019
pubmed:
20
8
2019
medline:
3
4
2020
Statut:
epublish
Résumé
Despite increasing global attention to non-communicable diseases (NCDs) and their incorporation into universal health coverage (UHC), the factors that determine whether and how NCDs are prioritized in national health agendas and integrated into health systems remain poorly understood. Childhood cancer is a leading non-communicable cause of death in children aged 0-14 years worldwide. We investigated the political, social, and economic factors that influence health system priority-setting on childhood cancer care in a range of low- and middle-income countries (LMIC). Based on in-depth qualitative case studies, we analyzed the determinants of priority-setting for childhood cancer care in El Salvador, Guatemala, Ghana, India, and the Philippines using a conceptual framework that considers four principal influences on political prioritization: political contexts, actor power, ideas, and issue characteristics. Data for the analysis derived from in-depth interviews (n = 68) with key informants involved in or impacted by childhood cancer policies and programs in participating countries, supplemented by published academic literature and available policy documents. Political priority for childhood cancer varies widely across the countries studied and is most influenced by political context and actor power dynamics. Ghana has placed relatively little national priority on childhood cancer, largely due to competing priorities and a lack of cohesion among stakeholders. In both El Salvador and Guatemala, actor power has played a central role in generating national priority for childhood cancer, where well-organized and -resourced civil society organizations have disrupted legacies of fragmented governance and financing to create priority for childhood cancer care. In India, the role of a uniquely empowered private actor was instrumental in creating political priority and establishing sustained channels of financing for childhood cancer care. In the Philippines, the childhood cancer community has capitalized on a window of opportunity to expand access and reduce disparities in childhood cancer care through the political prioritization of UHC and NCDs in current health system reforms. The importance of key health system actors in determining the relative political priority for childhood cancer in the countries studied points to actor power as a critical enabler of prioritization in other LMIC. Responsiveness to political contexts-in particular, rhetorical and policy priority placed on NCDs and UHC-will be crucial to efforts to place childhood cancer firmly on national health agendas. National governments must be convinced of the potential for foundational health system strengthening through attention to childhood cancer care, and the presence and capability of networked actors primed to amplify public sector investments and catalyze change on the ground.
Sections du résumé
BACKGROUND
Despite increasing global attention to non-communicable diseases (NCDs) and their incorporation into universal health coverage (UHC), the factors that determine whether and how NCDs are prioritized in national health agendas and integrated into health systems remain poorly understood. Childhood cancer is a leading non-communicable cause of death in children aged 0-14 years worldwide. We investigated the political, social, and economic factors that influence health system priority-setting on childhood cancer care in a range of low- and middle-income countries (LMIC).
METHODS AND FINDINGS
Based on in-depth qualitative case studies, we analyzed the determinants of priority-setting for childhood cancer care in El Salvador, Guatemala, Ghana, India, and the Philippines using a conceptual framework that considers four principal influences on political prioritization: political contexts, actor power, ideas, and issue characteristics. Data for the analysis derived from in-depth interviews (n = 68) with key informants involved in or impacted by childhood cancer policies and programs in participating countries, supplemented by published academic literature and available policy documents. Political priority for childhood cancer varies widely across the countries studied and is most influenced by political context and actor power dynamics. Ghana has placed relatively little national priority on childhood cancer, largely due to competing priorities and a lack of cohesion among stakeholders. In both El Salvador and Guatemala, actor power has played a central role in generating national priority for childhood cancer, where well-organized and -resourced civil society organizations have disrupted legacies of fragmented governance and financing to create priority for childhood cancer care. In India, the role of a uniquely empowered private actor was instrumental in creating political priority and establishing sustained channels of financing for childhood cancer care. In the Philippines, the childhood cancer community has capitalized on a window of opportunity to expand access and reduce disparities in childhood cancer care through the political prioritization of UHC and NCDs in current health system reforms.
CONCLUSIONS
The importance of key health system actors in determining the relative political priority for childhood cancer in the countries studied points to actor power as a critical enabler of prioritization in other LMIC. Responsiveness to political contexts-in particular, rhetorical and policy priority placed on NCDs and UHC-will be crucial to efforts to place childhood cancer firmly on national health agendas. National governments must be convinced of the potential for foundational health system strengthening through attention to childhood cancer care, and the presence and capability of networked actors primed to amplify public sector investments and catalyze change on the ground.
Identifiants
pubmed: 31425526
doi: 10.1371/journal.pone.0221292
pii: PONE-D-19-08465
pmc: PMC6699697
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221292Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Jpn J Clin Oncol. 2002 Mar;32 Suppl:S52-61
pubmed: 11959878
Lancet. 2007 Oct 13;370(9595):1370-9
pubmed: 17933652
J Cancer Res Ther. 2005 Oct-Dec;1(4):240-8
pubmed: 17998663
Lancet Oncol. 2008 Aug;9(8):721-9
pubmed: 18672210
Lancet. 2010 Jun 5;375(9730):2045-9
pubmed: 20569844
Lancet. 2010 Oct 2;376(9747):1186-93
pubmed: 20709386
Implement Sci. 2010 Sep 20;5:69
pubmed: 20854677
Lancet. 2011 Apr 23;377(9775):1438-47
pubmed: 21474174
Stud Health Technol Inform. 2013;183:251-6
pubmed: 23388293
Lancet Oncol. 2013 Mar;14(3):e125-35
pubmed: 23434339
Lancet Oncol. 2013 Mar;14(3):e104-16
pubmed: 23434340
Lancet. 2013 Jul 6;382(9886):65-99
pubmed: 23810020
Cancer. 2014 Jan 1;120(1):112-25
pubmed: 24132910
Pediatr Blood Cancer. 2014 Mar;61(3):572-6
pubmed: 24249518
Pediatr Blood Cancer. 2014 May;61(5):803-9
pubmed: 24376115
Pediatr Blood Cancer. 2014 Feb;61(2):345-54
pubmed: 24376230
PLoS Med. 2014 Jun 17;11(6):e1001656
pubmed: 24936984
Indian J Med Paediatr Oncol. 2014 Jul;35(3):226-7
pubmed: 25336795
Indian J Med Paediatr Oncol. 2014 Oct;35(4):288-90
pubmed: 25538407
Pediatr Blood Cancer. 2015 Sep;62(9):1609-15
pubmed: 25925227
BMC Med. 2015 Apr 29;13:101
pubmed: 25925656
Br J Cancer. 2015 Jun 9;112(12):1845-56
pubmed: 26042935
Lancet. 2015 Aug 29;386(9996):928-30
pubmed: 26138141
Lancet Glob Health. 2015 Aug;3(8):e487-e495
pubmed: 26187491
J Clin Oncol. 2015 Sep 20;33(27):3065-73
pubmed: 26304881
J Clin Oncol. 2016 Jan 1;34(1):53-61
pubmed: 26578620
Nurse Res. 2006 Jul 1;13(4):84
pubmed: 27702218
Lancet. 2017 Jan 7;389(10064):119-124
pubmed: 27717613
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Lancet Oncol. 2017 Jan;18(1):20-22
pubmed: 28049570
Lancet Haematol. 2017 May;4(5):e202-e217
pubmed: 28411119
Lancet Oncol. 2017 Jun;18(6):709-711
pubmed: 28593842
Cancer. 2018 Jan 15;124(2):391-397
pubmed: 28915337
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
J Psychosoc Oncol. 2018 May-Jun;36(3):319-332
pubmed: 29452054
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241165
Lancet Oncol. 2019 Apr;20(4):483-493
pubmed: 30824204